Jefferies reiterates Eli Lilly stock rating on GLP-1 data By Investing.com

Eli Lilly guided 2026 revenue of $80–83 billion and Jefferies reiterated a Buy with a $1,300 price target after prescription data showing oral Wegovy ~89,300 IMS prescriptions in its 10th week and ~80% retail share; Jefferies models ~$2.0B in orforglipron 2026 revenue vs $1.55B consensus. The company posted 44.7% revenue growth over the last 12 months, trades at a P/E of 40.13 (PEG 0.41), and TRANSCEND‑T2D‑1 Phase 3 retatrutide results met primary and key secondary endpoints, prompting price targets in the $1,281–$1,313 range from several firms.

Analysis

The market is treating Lilly as a multi-product growth franchise with structural optionality across both injectable and oral GLP-1-like modalities; the non-obvious lever is channel mix. A durable shift from specialty clinic dispensing to retail scripts compresses gross-to-net and shortens cash cycle for manufacturers, but it also transfers margin and negotiating power toward PBMs, retail chains, and wholesalers — these players will be the true marginal capture points for early revenue growth.

Supply-side frictions are the next choke point. Rapid adoption of new formats will ratchet demand for peptide synthesis capacity, fill-finish lines, and cold-chain logistics; those bottlenecks create a multi-quarter mismatch between prescriber demand and real-world fulfillment that can amplify weekly prescription volatility and produce noisy datapoints that mislead models. Data vendors that aggregate and monetize this flux (claims/retail panels) will see sticky revenue, but their datasets will also produce false signals if channel shifts aren’t normalized.

Regulatory and payer dynamics remain the primary asymmetric risk to current optimism. Payers can blunt uptake via utilization management and tiering faster than manufacturers can scale supply, so upside is concentrated in scenarios where pricing and access remain favorable; downside occurs if safety signals, stricter utilization, or accelerated generic competition in low‑cost markets pressure pricing. This creates a convex payoff for shareholders: binary regulatory/coverage wins unlock multi-year re-rating while operational setbacks compress forward multiples quickly.

Key Decisions for Investors

• Long LLY via a calendar/diagonal call spread (buy 12–18 month slightly OTM calls, sell 1–3 month near‑term calls) to capture multi‑quarter product rollouts while funding premium with near‑term theta; target 2.0–3.0x upside if execution and access remain favorable, max loss = net premium (~100% of premium).
• Long IQV (IQV) modestly (6–12 month horizon) to play higher data/analytics demand from rapid launch cycles and channel-shift noise; expect 10–20% upside if clients increase panel/analytics spend, hedge with 5–7% portfolio position size due to execution risk.
• Pair trade for idiosyncratic risk: long LLY / short a small-cap weight‑loss/GLP-1 peer (or small-cap biotech basket) to isolate product execution and scale risk; size the short to equal 30–50% notional of the long and maintain 3–6 month rebalancing to manage flow-driven volatility.
• Buy limited downside protection for LLY (6–9 month OTM puts ~10–15% strike) sized to cap drawdown on 25–35% of the position if payer/access pushes back — cost should be weighed against probability of access tightening within 12 months.
• Event-monitoring alert: treat weekly prescription panel spikes as noisy inputs — only increment exposure after consistent multi‑month retail dispensation trends and confirmation of supply chain stability (3 consecutive months).